Mitsubishi Tanabe Pharma has formed a strategic collaboration with Medicago to develop at least three new vaccines based on the Canadian company’s plant-based virus-like particles (VLP) technology. The two companies will initially develop a rotavirus-like particle (RLP) vaccine target and Mitsubishi Tanabe will provide all R&D funding. The Japanese company will have the option to license the RLP vaccine target for up to CDN$30 M (US$33 M) in upfront and milestone payments plus royalties.